BioSpace News Archive

Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando, Florida.

Paragonix Technologies, Inc., the leading organ transplant company, presented impactful clinical data on the use of its Advanced Organ Preservation system, LUNGguard™, in a study presented at this year’s ISHLT Annual Meeting & Scientific Sessions.

Viridian Therapeutics, Inc. announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease —including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, to be held April 23-27, 2023, in New Orleans, Louisiana.

Centene Corporation announced it has named Anika Gardenhire RN, BSN, MMCI as its Chief Customer Experience Officer.

Phio Pharmaceuticals Corp. announced the closing of its previously announced registered direct offering of 353,983 shares of common stock, at a purchase price of $5.65 per share, priced at-the-market under Nasdaq rules.

Hyperfine, Inc., the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable MRI system™, announced that it will report financial results for the first quarter 2023 on Thursday, May 11, 2023.

Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to thirty two new employees to purchase an aggregate of 236,000 ordinary shares under Avadel’s 2021 Inducement Plan.

QIAGEN announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined the Supervisory Board as a new member and will stand for election at the next Annual General Meeting scheduled for June 22, 2023.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent business highlights.